By Colin Kellaher
Eli Lilly said an experimental drug nearly eliminated an inherited type of bad cholesterol at its highest dose in a mid-stage study.
Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein(a), or lp(a), met its primary endpoint, reducing lp(a) levels by an average of 93.9% over the 60- to 180-day period after treatment with the highest tested dose of 400 milligrams.
The Indianapolis drugmaker said study participants who received the 16-milligram and 96-milligram lepodisiran doses saw reductions of 40.8% and 75.2% in lp(a) levels, respectively.
About 20% of Americans have high levels of lp(a), which is genetic and has been linked to increased risk for heart attack, stroke and other cardiovascular diseases. There are currently no FDA-approved drugs to lower lp(a) levels.
Eli Lilly said it will continue to evaluate the potential benefits of lepodisiran in an ongoing Phase 3 study.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 31, 2025 06:56 ET (10:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.